Definitive Healthcare (DH) Q3 2026 earnings review
Definitive Healthcare beats profit targets, but sales keep falling
Definitive Healthcare, a seller of healthcare commercial data and analytics, beat its third-quarter profit plan while its sales kept shrinking. Revenue dropped 9% from a year ago to $54.7 million, and unearned customer billings on the balance sheet fell 12% by our math. New chief executive Clay Ritchey said the results show the "underlying health of the business", as cost cuts lifted operating profit excluding one-offs above the company's target for a seventh straight quarter.
| Revenue | $54.7M -9.0% from a year ago |
|---|---|
| Profit before interest, taxes, depreciation, and one-offs (Adjusted EBITDA) | $15.7M 28.8% of revenue; beat $13.5–14.5M plan |
| Total deferred revenue | $80.7M -12.3% from a year ago by our math |
| Full-year outlook | Withdrawn suspended after Advent buyout proposal |
⚖️ Verdict: 🔴 Bearish
The story got worse because controlling shareholders proposed a buyout while revenue and unearned customer cash are still falling, and the company shut off its forward outlook and conference call. One bright spot: excluding a one-time data credit from a year ago, profit margins held nearly steady at 29% of sales, and net cash rose to $31 million by our math.
The question now is whether public shareholders will see a turnaround in winter contract renewals or get bought out first by Advent International and founder Jason Krantz. Either the upcoming quarterly filing shows the 12% drop in contracted backlog is easing, or the special committee negotiates a sale while revenue is still shrinking. The third-quarter Form 10-Q backlog footnote and the special committee's next announcement will settle it.
🐂 Bull Case
Cost Cuts Keep Operating Profit Above Plan
Definitive Healthcare sells subscription access to healthcare commercial data, and it has cut operating expenses all year to protect profit while sales shrink. In the third quarter, profit before interest, taxes, depreciation, and one-offs (Adjusted EBITDA) reached $15.7 million, or 28.8% of revenue, beating the $13.5 million to $14.5 million target.
Headline profit on that measure fell 16.9% from $18.9 million a year ago, when the margin was 31.6%. That comparison is distorted because the year-ago quarter included a $1.5 million one-time credit from a data contract. By our math, excluding that credit leaves the prior-year margin at 29.1%, so underlying profitability held nearly steady despite a 9.0% drop in sales.
Lower spending in two departments carried the margin: product development fell 0.4 percentage points of revenue to 12.2%, and stock-based pay fell 1.0 percentage point to 10.1%. Beating this profit target for a seventh straight quarter shows tight cost control, though cost cuts alone cannot grow cash flow indefinitely if sales keep falling.
What to watch: operating expenses in the upcoming third-quarter Form 10-Q filing. A further drop in product development and sales headcount costs would show whether profit margins can stay near 29% through the fourth quarter.
Claims Data Integrations Win Six-Figure Contracts
The company has spent the past year fixing its medical claims data supply and building direct software links to stop customers from leaving for cheaper rivals. While the release gave no update on the Turbo artificial intelligence platform pilot, it detailed two large deals that show how clean data feeds win business.
A life sciences customer signed a new contract worth several hundred thousand dollars after "struggling with stale data and the complexity of ingesting and interpreting claims" from prior vendors. In a second deal, a medical malpractice insurer signed a six-figure expansion at renewal that roughly doubled its spending, using a direct Snowflake data link to replace manual file transfers.
These wins matter because life sciences customers have been cutting their spending since late 2024, while diversified insurance and healthcare provider customers have steadied. Winning multi-hundred-thousand-dollar contracts proves that pairing physician affiliation directories with monthly claims still commands high prices when delivered directly into a customer's workflow.
What to watch: revenue from existing customers versus new customers in the third-quarter Form 10-Q filing. A smaller drop in existing-customer revenue than last quarter's $7.8 million decline would show these expansions are starting to offset cancellations.
🐻 Bear Case
Advent Buyout Proposal Freezes Public Disclosures
In the first half of 2026, Definitive Healthcare quietly spent $2.0 million on legal and advisory fees for an "evaluation of strategic, financial, tax, and capital structure alternatives". On September 2, that review surfaced publicly when the board's special committee received a "non-binding indication of interest from Advent International, L.P." and founder Jason Krantz to buy the rest of the company.
Advent and Krantz already control more than half of the combined voting shares. Because of the buyout proposal, the healthcare data provider announced it "will not provide financial guidance or host a conference call" for the third quarter. Meanwhile, third-quarter legal and advisory fees outside core operations rose to $1.4 million, up from $0.3 million a year ago.
This matters because public shareholders are left without forward targets or executive commentary while the controlling shareholders negotiate a potential buyout. In addition, the company carries an $11.8 million Tax Receivable Agreement liability, a contract that pays tax savings to early owners and can require an immediate lump-sum payout if control of the company changes.
What to watch: any formal merger agreement or update from the board's special committee, alongside the Tax Receivable Agreement footnote in the Form 10-Q. A binding buyout offer or a disclosed change-of-control payout figure will determine what public Class A shareholders actually receive.
Sales and Unearned Customer Cash Keep Shrinking
New chief executive Clay Ritchey struck an upbeat tone in his first quarterly release. "This quarter’s results demonstrate the underlying health of the business and a solid foundation to build upon," Ritchey said. The accounting numbers in the tables tell a harder story.
- Third-quarter revenue: $54.7 million, down 9.0% from a year ago and down 1.0% from the second quarter
- Total deferred revenue (cash billed for future service): $80.7 million, down 12.3% from a year ago by our math
- Sequential deferred revenue outflow: down $8.7 million from June, following a $9.8 million drop in the second quarter
- Accounts receivable: $29.5 million, down 14.1% from $34.4 million a year ago by our math
Deferred revenue is the clearest balance-sheet read on future subscription sales in this release, and its 12.3% drop matches the 12% decline in contracted 12-month backlog reported over the prior three quarters. Sales are still shrinking at nearly 9% a year, and the shrinking pool of unearned customer billings shows the top line has not yet stabilized.
What to watch: current remaining performance obligations (contracted revenue for the next 12 months) in the Form 10-Q filing. A decline worse than last quarter's 12% drop would show that customer contract values are still shrinking heading into the peak winter renewal season.
Risks this quarter didn't answer
Because the company cancelled its conference call and shortened its press release, five standing operational and listing questions received no reading today.
- Contracted 12-month backlog (cRPO): not in the release; the Form 10-Q backlog footnote will show whether the 12% yearly decline improved or worsened.
- Customer retention rate (net dollar retention): missing after two quarters of reported improvement; only the year-end Form 10-K or a resumed call will show if December renewals hold up.
- Sales by customer group: subscription versus professional services mix and life sciences performance await the Form 10-Q revenue table.
- Turbo AI general availability: targeted for late 2026, with no launch or pricing update in the release.
- Nasdaq minimum-bid compliance: the Form 10-Q will show any plan to cure the sub-$1.00 share price notice before the December 15, 2026 deadline.
👓 Other Themes
Clay Ritchey Takes Over as Chief Executive
Clay Ritchey issued the third-quarter commentary as chief executive officer, succeeding Kevin Coop, who led the company during the second quarter. In the third quarter, the firm recorded $1.0 million in consulting and severance costs for strategic transition initiatives, alongside an announcement of additional executive appointments to lead artificial intelligence projects.
💲 Other KPIs
Cash and short-term investments rose to $190.0 million while total term-loan debt fell to $158.5 million, lifting net cash by our math to $31.5 million from $23.0 million last quarter. Steady operating cash flow and the absence of share buybacks have doubled net cash since the start of the year.
Unlevered free cash flow — operating cash flow minus capital spending, with cash interest and one-off restructuring and legal payments added back — fell 27.4% from $17.9 million a year ago. It represented 23.8% of revenue in the quarter, up from 21.0% in the second quarter as receivable collections outpaced capital spending.
Total fully diluted shares, which include all unvested employee stock units and convertible partnership units, rose 6.2% from 156.6 million a year ago. Definitive Healthcare has not repurchased any shares in 2026 after letting its prior buyback authorization expire at the end of 2025, so employee stock grants continue to expand the share count.
🔮 Guidance
Withdrawn. Definitive Healthcare suspended its full-year and fourth-quarter financial outlook following the September 2 non-binding buyout proposal from Advent International and founder Jason Krantz. Before the suspension, the full-year plan called for $220.0 million to $222.0 million in revenue (an 8% to 9% decline) and $57.0 million to $59.0 million in Adjusted EBITDA.
❓ Key Questions
What happened to contracted 12-month backlog in Q3?
Total deferred revenue fell 12.3% from a year ago, but the press release omitted current remaining performance obligations (cRPO). Investors need the Form 10-Q backlog note to see if contracted demand finally broke out of its three-quarter 12% decline.
Did customer retention improve for a third straight quarter?
Before cancelling the call, management pointed to two consecutive quarters of improving trailing 12-month net dollar retention as its main turnaround proof. Without that reading or the actual retention percentage, outsiders cannot verify if customer cancellations are slowing.
What is the Tax Receivable Agreement payout in a buyout?
Advent International and founder Jason Krantz proposed taking the company private. Because a change of control can accelerate the $11.8 million Tax Receivable Agreement liability, public Class A shareholders need to know how much cash would go to early unit holders first.
Did subscription revenue hold flat from the second quarter?
Prior commentary called for third-quarter subscription revenue to stay flat sequentially at $52.8 million while professional services grew double digits. The Form 10-Q revenue table will show whether core subscriptions actually stopped shrinking quarter over quarter.